Askel Healthcare has reached an important milestone towards marketing authorization of the COPLA® implant in EU and the USA
Finnish medical technology company Askel Healthcare is developing a new method to treat knee cartilage defects. Askel Healthcare's COPLA® implant is expected to significantly accelerate rehabilitation and enable healing of damaged knee cartilage. From the beginning of January, COPLA® implant is available for selected patients as part of a clinical trial. Three Finnish and one Estonian hospital are participating in the trial. The company is aiming to commercialize the product in the United States and EU by 2028.Knee pain is very common. It is estimated that every fourth 40-year-old person